

The Effect of Folate and Vitamin B6 on Endothelial Function in Children with Type 1 Diabetes

Dr Karen Ellen MacKenzie

Department of Paediatrics

School of Medicine

University of Adelaide

2009

A Thesis Submitted for the Degree of Doctor of Philosophy

The Effect of Folate and Vitamin B6 on Endothelial Function in Children with Type 1 Diabetes

Dr Karen E MacKenzie

Table of Contents

Abstract	11
Introduction.....	11
Methods.....	12
Results	12
Conclusions.....	13
Acknowledgments	14
List of Tables	15
List of Figures	17
Abbreviations	19
Units	21
Chapter 1. Introduction	22
Problem Statement.....	22
Generation of Hypotheses	24
Aims	25
Research Strategy	26
Chapter 2. Background	29
Type 1 Diabetes	29
Type 1 Diabetes- Definition and Incidence.....	29
Hypotheses for the Aetiology and Increasing Incidence of T1DM	31
The Hygiene Hypothesis	31
The Accelerator Hypothesis	32
Vitamin D Hypothesis.....	34
Impact of Type 1 diabetes	35
Type 1 Diabetes- a Historical Perspective	36
Endothelium and Atherosclerosis	44
Anatomy of the Blood Vessel	44

Normal Endothelium.....	44
The Endothelium and Nitric Oxide.....	45
Endothelial Dysfunction.....	47
Endothelial Dysfunction and the Development of Atherosclerosis	47
Atherosclerosis in Children	51
Measurement of Endothelial Dysfunction.....	52
Endothelial Dysfunction and Diabetes	54
Endothelial Dysfunction in Children with Type 1 Diabetes	55
Recognised Contributory Factors to Endothelial Dysfunction.....	56
Diet	56
Exercise	56
Puberty	56
Smoking.....	57
Insulin	57
Reversibility of Endothelial Dysfunction.....	58
Diabetes and Vascular Disease	59
Macrovascular Complications	59
Cardiovascular Disease.....	59
Cerebrovascular Disease	61
Microvascular Complications	62
Retinopathy.....	62
Nephropathy	62
Neuropathy	64
Mechanisms underlying Vascular Disease in Diabetes.....	65
Polyol Pathway and Aldose Reductase.....	67
Advanced Glycation End (AGE) Products	68
The Hexosamine Pathway.	70
Protein Kinase C and Diacylglycerol	70
Reactive Oxygen Species and Oxidative Stress.....	72
Nitric Oxide	73
Free Fatty Acids.....	74
Summary	74
Homocyst(e)ine.....	75
Homocyst(e)ine: The Background.....	75
Metabolism of Homocysteine.....	76

Pathogenic Mechanism of Hyperhomocyst(e)inaemia	78
Homocyst(e)ine and Vascular Disease	80
Homocyst(e)ine and Diabetes.....	81
The Controversies	83
Folate.....	85
Folate in the Prevention of Disease.....	85
Folate and Homocyst(e)ine.....	86
Folate Status, Homocyst(e)ine and Endothelial Function in Type 1 Diabetes	87
Folate and Nitric Oxide	90
Folate and Antioxidant Actions	91
Folate Dose	91
Safety Considerations.....	92
Vitamin B6.....	94
Vitamin B6 Metabolism	94
Measurement of Vitamin B6.....	95
Vitamin B6 and Homocyst(e)ine	95
Vitamin B6 and Vascular Disease.....	96
Vitamin B6 and Diabetes	97
Vitamin B6 and Inflammation	97
Vitamin B6 and Safety Considerations:.....	98
Adverse Effects of Vitamin B6 and Neuropathy.....	98
Vitamin B6 Dose.....	99
High Sensitivity C-Reactive Protein	100
Hs-CRP in Cardiovascular Disease.....	100
Hs-CRP and Diabetes.....	101
Hs-CRP in Children.....	102
CRP and Vitamin B6	103
Summary	104
Chapter 3. Methods	106
Clinical Methods:	106
Subjects	106
Control Subjects.....	107
Ethical approval	108

Laboratory Methods:.....	110
Total Plasma Homocyst(e)ine (tHcy).....	110
Serum and Red Cell Folate.....	111
Vitamin B12.....	111
Vitamin B6.....	111
Haemoglobin A1c (HbA1c).....	112
Lipids.....	112
High Sensitivity C-Reactive Protein.....	114
Cotinine.....	114
Thyroid Function.....	115
Coeliac Screen.....	115
Assessment of Endothelial Function.....	116
Flow Mediated Dilatation.....	116
Equipment.....	116
Subject Preparation.....	116
Image Acquisition.....	117
Endothelium-dependent Flow Mediated Dilatation.....	120
Endothelium-independent Vasodilatation with Glyceryl Trinitrate.....	123
Analysis.....	125
Timing of FMD.....	125
Application of Flow Mediated Dilatation in Clinical Trials.....	126
Statistical Methods.....	127
Chapter 4. Publication.....	128
Folate and Vitamin B6 rapidly normalize endothelial dysfunction in children with Type 1 Diabetes.....	128
Pediatrics 2006 Jul;118(1):242-53.....	128
Chapter 5. The immediate effect of folate and vitamin B6 on endothelial function in children and adolescents with type 1 diabetes.....	141
Introduction.....	141
Background.....	141
Hypothesis.....	142
Aims.....	143
Outcome Measures.....	143
Study Design.....	143
Subjects.....	145

Ethical approval	145
Study Protocol and Laboratory Methods	146
Biochemical Parameters	146
Biochemical Assays	147
Non-invasive Measure of Endothelial Function	147
Statistics	147
Results	149
Subjects	149
Baseline Characteristics	149
Baseline Biochemical Parameters	150
Baseline Endothelial Function	151
Change in Flow Mediated Dilatation (FMD)	154
Change in GTN-Induced Dilatation	156
Change in FMD: GTN	157
Serum Folate	158
Red Cell Folate	160
Vitamin B6: Pyridoxine Phosphate Activation	161
Total Plasma Homocyst(e)ine (tHcy)	162
Glucose	163
High Sensitivity C-Reactive Protein (Hs-CRP)	164
Correlates of Change in FMD	164
Discussion	166
Summary	170
Chapter 6. The four and eight week effect of folate and vitamin B6 on endothelial function in children and adolescents with type 1 diabetes	171
Introduction	171
Background	171
Hypotheses	172
Aims	172
Outcome Measures	173
Study Design	173
Subjects	174
Ethical Approval	174
Study Protocol and Laboratory Methods	175
Biochemical Parameters	175

Biochemical Assays	176
Non-invasive Measure of Endothelial Function.....	176
Statistics	177
Results	179
Subjects	179
Baseline Characteristics.....	179
Baseline Biochemical Parameters.....	181
Baseline Endothelial Function	182
Correlates of Baseline Endothelial Function.....	183
Flow Mediated Dilatation (FMD)	185
GTN-Induced Dilatation.....	187
FMD: GTN	188
Serum Folate and Red Cell Folate	189
Vitamin B6: Pyridoxine Phosphate Activation.....	191
Total Plasma Homocyst(e)ine (tHcy).....	192
High Sensitivity C-Reactive Protein (Hs-CRP).....	193
Glucose.....	193
Correlates of Change in Flow Mediated Dilatation.....	195
Additive Effect of Vitamin B6.....	197
Adherence	198
Discussion	199
Summary	202
Chapter 7. Subjects who Participated in Both the Immediate and Eight Week	
Studies.	203
Introduction.....	203
Results	203
Summary	211
Chapter 8. Publication:.....	212
High sensitivity-CRP is associated with weight, BMI and female sex but not with endothelial function in children with type 1 diabetes.....	212
Pediatric Diabetes. 2009 Feb 1;10(1):44-51. Epub 2008 Sep 15.	212
Chapter 9. Hs CRP	221
Introduction.....	221
Background	221

Results.....	224
Four Hour Study.....	224
Eight Week Study	225
Further Analysis.....	229
Discussion	230
Summary	232
Chapter 10. GTN- Induced Vasodilatation.....	233
Introduction.....	233
Background	233
Results	235
GTN- Induced Dilatation and Systolic Blood Pressure.....	237
GTN- Induced Dilatation and HDL- Cholesterol.....	238
GTN- Induced Dilatation and BMI.....	239
Discussion	241
Summary and Implications.....	243
Chapter 11. Unexpected Findings and Limitations	244
The Placebo Group	244
Smokers	245
Resting Vessel Diameters	245
Stimulus for FMD.....	247
Improvement in FMD	248
GTN Dose	249
Hs-CRP	250
Chapter 12. Discussion	253
Introduction.....	253
Strengths and Weaknesses.....	254
Precision.....	255
Validity.....	256
Internal Validity	256
Selection Bias	257
Information Bias	258
Confounding.....	258
External Validity	259
Summary	260

Study Results and Conclusions	261
The Immediate Effects of Folate and Vitamin B6 on Endothelial Function in Children and Adolescents with Type 1 Diabetes.	261
The Eight Week Effect of Folate and/or Vitamin B6 on Endothelial Function in Children and Adolescents with Type 1 Diabetes.	262
High Sensitivity C-Reactive Protein.....	263
Study Implications.....	264
Directions for Future Research.....	265
Appendices	270
Appendix 1. Consent Form.....	270
Appendix 2. Information Sheets	272
Appendix 3. Budget.....	278
References	282

Abstract

Introduction

Endothelial dysfunction is a precursor of vascular disease. Children at high risk of vascular disease including children with type 1 diabetes (T1DM) have marked endothelial dysfunction. Endothelial dysfunction is reversible occurring early in the time-line of atherosclerosis. The detection of endothelial dysfunction in childhood allows the study of interventions at an early and potentially reversible stage of vascular damage.

We have previously shown that endothelial dysfunction is common in children with T1DM and relates to folate status (Wiltshire, Gent *et al.* 2002) despite higher serum and red cell folate levels and lower total plasma homocyst(e)ine (tHcy) than healthy controls (Wiltshire, Thomas *et al.* 2001; Wiltshire and Couper 2004). Even with these higher folate levels, in a pilot, cross-over study we have shown that folate supplementation improves endothelial function in children with T1DM (Pena, Wiltshire *et al.* 2004).

Beneficial effects of folate on endothelial function are being demonstrated in increasing numbers of studies (Verhaar, Wever *et al.* 1998; Woo, Chook *et al.* 1999; Doshi, McDowell *et al.* 2001; Thambyrajah, Landray *et al.* 2001; van Etten, de Koning *et al.* 2002; Woo, Chook *et al.* 2002). Improvement in endothelial function, has also been observed within hours of additional oral folate (Doshi, McDowell *et al.* 2002) and within minutes of intravenous 5-methyltetrahydrofolate (MTHF), the active form of folate (Verhaar, Wever *et al.* 1998; van Etten, de Koning *et al.* 2002).

Treatment with combination folate and vitamin B6 lowers markers of endothelial activation (Constans, Blann *et al.* 1999; Vermeulen, Stehouwer *et al.* 2000). However, there is limited literature examining the effect of B6 alone on the endothelium. Vitamin B6 improves endothelial function in cardiac transplant recipients (Miner, Cole *et al.* 2001). There is no data examining the effect of supplemental vitamin B6 in T1DM or children at risk of vascular disease.

Atherosclerosis is an inflammatory process and high-sensitivity C-reactive protein (Hs-CRP), a marker of inflammation, predicts cardiovascular events in adults. Elevated Hs-

CRP in otherwise healthy children is associated with impaired endothelial function. Similar studies in children with T1DM have not been performed.

We therefore aimed to determine the effects, acutely, of folate and vitamin B6 on endothelial function, and over eight weeks, of folate and vitamin B6, alone and in combination, on endothelial function. In addition, we sought to determine whether Hs-CRP, is associated with vascular endothelial and smooth muscle dysfunction, in children with T1DM and healthy control subjects.

Methods

A randomised, double-blind, placebo-controlled study of folate 5mg daily and vitamin B6 100mg daily in 124 children with T1DM determined the immediate and eight week effects of these vitamins, alone and in combination, on endothelial function. Endothelial function, assessed by flow mediated dilatation(FMD) and glyceryl-trinitrate(GTN)-induced dilatation using high resolution ultrasound of the brachial artery, was measured at baseline, at two and four hours after the first dose (n=35), and at four and eight weeks of treatment (n=122). Serum and red cell folate, serum vitamin B6, Hs-CRP, tHcy, HbA1c and blood glucose were measured at each assessment of endothelial function.

Hs-CRP and endothelial function, were measured at baseline, in 121 subjects with T1DM. 31 subjects with T1DM that were randomised to receive placebo treatment were studied at four and eight weeks and were included in the longitudinal analysis of Hs-CRP and endothelial function. Hs-CRP and endothelial function were also studied in 33 age-matched, healthy control subjects.

Results

FMD normalised in all treatment groups. At baseline and eight weeks FMD [mean(SD)] on folate improved from 2.6(4.3)% to 9.7(6.0)%($p<0.001$), on vitamin B6 from 3.5(4.0)% to 8.3(4.2)%($p<0.001$), and on folate/vitamin B6 from 2.8(3.5)% to 10.5(4.4)%($p<0.001$) respectively. This improvement in FMD occurred within two hours and was maintained

over eight weeks for each treatment. FMD in the placebo group, and GTN-induced dilatation in all groups, did not change. Increase in serum folate, red cell folate, and vitamin B6 related to increase in FMD. Improvement in FMD was independent of change in tHcy, glucose, HbA1c and Hs-CRP. Baseline red cell folate and baseline diastolic blood pressure inversely related to improvement in FMD. Serum triglycerides and LDL-cholesterol inversely related to baseline FMD.

Hs-CRP did not differ between subjects with T1DM and healthy, age-matched controls. In both controls and subjects with T1DM, Hs-CRP did not relate to FMD or GTN-induced dilatation at baseline or at intervals over eight weeks in subjects with T1DM. Hs-CRP did not change over time. In T1DM, but not healthy controls, Hs-CRP related to BMI z-score($r=0.47, p<0.001$), weight z-score($r=0.41, p<0.001$) and female sex($p=0.008$).

Conclusions

High dose folate and vitamin B6 rapidly normalise endothelial dysfunction in children with T1DM. This effect is maintained over eight weeks with ongoing supplementation. Combination treatment over eight weeks does not confer additional benefit.

Hs-CRP is not associated with early vascular dysfunction in children with T1DM. However, in children and adolescents with T1DM, Hs-CRP is associated with female sex and children with higher BMI suggesting these groups may be at greater cardiovascular risk.

In addition to optimising metabolic control, intervention with folate or vitamin B6, at an early stage in childhood, could have a major impact on long-term diabetic vascular complications, and requires further investigation. Maintenance of a healthy BMI may be important in the prevention of vascular disease of T1DM.

Acknowledgments

I would like to thank a number of people in help completing this Thesis.

Firstly and foremost, I would like to acknowledge my supervisors Professor Jenny Couper and Dr Esko Wiltshire. I am enormously grateful for the hard work and support they have provided to me over the years of my Fellowship and Thesis writing.

I would also like to thank the numerous other people involved in assisting me with various aspects of the study. Most importantly:

Roger Gent and Lino Piotto the ultrasonographers, who tirelessly gave up their morning sleep-ins and weekends to perform the vascular ultrasounds of the children.

Craig Hirte for patiently, meticulously and tirelessly answering my statistical questions.

The young people with type 1 diabetes and to their families who participated in the study who showed dedication and enthusiasm to participate and complete the study.

Recognition also goes to the laboratory staff at the Women's and Children's Hospital and at the Institute of Medical and Veterinary Science for performing the laboratory measurements, Judy Miller, pharmacist, at Women's and Children's Hospital for performing the subject randomisation and dispensing of study medication, Karina Butcher, dietitian, at the Department of Nutrition at the Women's and Children's Hospital for her advice regarding appropriate meals for the children participating in the Immediate Effects Study and the Department of Food Services at the Women's and Children's Hospital for providing the meals.

I would like to acknowledge the financial support provided by a fellowship from the Juvenile Diabetes Research Foundation of Australia and the Royal Australasian College of Physicians.

Finally I would like to thank my family, my husband Brandon Rickards, my parents Neil and Pam MacKenzie who hung in there supporting me throughout the years of this Thesis and now also my little son Harry for sparing me to complete this work.

List of Tables

Table 1. Study Protocol for the Immediate Effects Study	146
Table 2. Baseline Clinical Characteristics, Immediate Effects Study	149
Table 3. Baseline Biochemical Parameters, Immediate Effects Study	151
Table 4. Baseline Endothelial Function, Immediate Effects Study.....	152
Table 5. Correlates of Baseline FMD, Immediate Effects Study.....	153
Table 6. FMD over Four Hours	154
Table 7. GTN-Induced Dilatation over Four Hours	156
Table 8. FMD: GTN over Four Hours.....	157
Table 9. Adjusted Serum Folate over Four Hours	159
Table 10. Change in RCF over Four Hours.....	160
Table 11. Change in Pyridoxine Phosphate Activation over Four Hours	161
Table 12. Change in tHcy over Four Hours.....	162
Table 13. Change in Glucose over Four Hours	163
Table 14. Correlates of change in FMD with Baseline Variables.....	164
Table 15. Correlates of Change in FMD with Change in Other Variables.....	165
Table 16. Study Protocol for the Eight Week Study	175
Table 17. Baseline Characteristics, Eight Week Study.....	180
Table 18. Baseline Biochemical Parameters, Eight Week Study.....	181
Table 19. Baseline Endothelial Function, Eight Week Study	182
Table 20. Correlates of Baseline FMD and Baseline GTN-Induced Dilatation.....	183
Table 21. Final multivariable ANOVA for FMD	184
Table 22. Final multivariable ANOVA for GTN-Induced Dilatation.....	184
Table 23. The relationship between Baseline Endothelial Function and Sex.....	184
Table 24. Change in Flow Mediated Dilatation over Eight Weeks	185
Table 25. Change in GTN-Induced Dilatation over Eight Weeks.....	187
Table 26. Change in FMD: GTN over Eight Weeks.....	188
Table 27. Correlates of the Change in FMD to Baseline Variables, Eight Week Study..	195
Table 28. Correlates for Change in FMD and Change in Other Variables, Eight Week Study.	196
Table 29. Adherence	198
Table 30. FMD Mean (SD).....	204
Table 31. Pearson's correlations for the change in baseline FMD between the Immediate effects study and eight week study	207

Table 32. Change in High Sensitivity C-Reactive Protein.....	224
Table 33. Comparison of Baseline Variables between Hs-CRP Groups.....	227
Table 34. Resting Vessel Diameter (mm) for the Immediate Effect Study	246
Table 35. Resting Vessel Diameter (mm) for the Eight Week Study	246
Table 36. Immediate Effect Study: Stimulus for FMD. % Increase in Blood Flow (m/s).	247
Table 37. Eight Week Study: Stimulus for FMD. % Increase in Blood Flow (m/s)	248

List of Figures

Figure 1. Atherosclerosis Time-line.....	48
Figure 2. Atherosclerosis (Ross 1999).....	49
Figure 3. Atherosclerosis (Ross 1999).....	49
Figure 4. Atherosclerosis (Ross 1999).....	50
Figure 5. Atherosclerosis (Ross 1999).....	51
Figure 6. A Summary of the Four Hyperglycaemia Induced Pathways (Brownlee 2001).....	66
Figure 7. Consequences of PKC Activation (Brownlee 2001)	71
Figure 8. Homocysteine Metabolism (Welch and Loscalzo 1998).....	77
Figure 9. Mechanisms of the Atherogenic Propensity of Homocyst(e)ine (Welch and Loscalzo 1998)	79
Figure 10. FMD Changes Over Time by Treatment Group.....	89
Figure 11. Serum Folate Changes Over Time by Treatment Group.....	89
Figure 12. Flow chart of recruitment	109
Figure 13. Ultrasound of the Brachial artery: Subject at Rest.....	118
Figure 14. Ultrasound of the Brachial artery: Subject at Rest.....	119
Figure 15. Brachial Arterial Flow Velocity: At Rest.....	119
Figure 16. Endothelium-dependent Flow Mediated Dilatation	120
Figure 17. Brachial Arterial Flow Velocity: During Cuff Inflation	121
Figure 18. Ultrasound of the Brachial Artery: During Cuff Inflation	122
Figure 19. Arterial Flow Velocity: During Reactive Hyperaemia	122
Figure 20. Ultrasound of the Brachial Artery: Third resting scan	123
Figure 21. Ultrasound of the Brachial Artery: Post GTN.....	124
Figure 22. FMD over Four Hours	155
Figure 23. GTN-Induced Dilatation over Four Hours.....	156
Figure 24. FMD: GTN over 4 Hours	157
Figure 25. Serum Folate over 4 hours	158
Figure 26. Red Cell Folate over Four Hours	160
Figure 27. Pyridoxine Phosphate Activation over Four Hours	161
Figure 28. tHcy over Four Hours.....	162
Figure 29. Glucose over Four Hours.....	163
Figure 30. FMD over Eight Weeks.....	186
Figure 31. GTN-Induced Dilatation over Eight Weeks.....	187
Figure 32. FMD: GTN-Induced Dilatation over Eight Weeks.....	188

Figure 33. Serum Folate over Eight Weeks	189
Figure 34. Red Cell Folate over Eight Weeks.	190
Figure 35. Pyridoxine Phospahte Activation over Eight Weeks.....	191
Figure 36. tHcy over Eight Weeks.....	192
Figure 37. Glucose over Eight Weeks.....	193
Figure 38. HbA1c over Eight Weeks	194
Figure 39. Change in FMD of Folate and Folate/ B6 Groups	197
Figure 40. FMD. Folate followed by Folate/Placebo Group (n= 14).....	205
Figure 41. FMD. Vitamin B6 followed by Vitamin B6/ Placebo Group (n= 5).	205
Figure 42. FMD. Vitamin B6 followed by Vitamin B6/Folate Group (n= 7)	206
Figure 43. FMD. Placebo followed by Placebo/Placebo Group (n= 9).....	206
Figure 44. Correlation between the change in FMD at two hours with the change in FMD at four hours.	208
Figure 45. Correlation between the change in FMD at two hours with the change in FMD at four weeks.	208
Figure 46. Correlation between the change in FMD at two hours with the change in FMD at eight weeks.....	209
Figure 47. Correlation between the change in FMD at four hours with the change in FMD at four weeks.	209
Figure 48. Correlation between the change in FMD at four hours with the change in FMD at eight weeks.....	210
Figure 49. Correlation between the change in FMD at four weeks with the change in FMD at eight weeks	210
Figure 50. Geometric mean of Hs-CRP over Four Hours.....	224
Figure 51. Geometric mean of Hs-CRP over Eight Weeks.....	226
Figure 52. Scatterplot Diagram: The Relationship between Baseline GTN-Induced Dilatation and Baseline FMD.	236
Figure 53. Scatterplot Diagram: The Relationship between Baseline GTN-Induced Dilatation and Systolic Blood Pressure.	237
Figure 54. Scatterplot Diagram: The Relationship between GTN- Induced Dilatation and HDL-Cholesterol (ln).	238
Figure 55. Scatterplot Diagram: The relationship between GTN-Induced Dilatation and BMI Z-score.....	239
Figure 56. GTN- Induced Dilatation relates to BMI Z-Score	240

Abbreviations

2D	Two-dimensional
ACE	Angiotensin converting enzyme
AER	Albumin excretion rate
AGEs	Advanced glycation end products
AST	Aspartate aminotransferase
BH ₂	Dihydrobiopterin
BH ₄	Tetrahydrobiopterin
cGMP	cyclic 3'5' guanosine monophosphate
CHD	Coronary heart disease
CRP	C-reactive protein
CYWHS	Children, Youth and Women's Health Service
DAG	Diacylglycerol
DCCT	Diabetes Control and Complications Trial
DKA	Diabetic ketoacidosis
ECG	Electrocardiogram
EDIC	Epidemiology of Diabetes Interventions and Complications
EDRF	Endothelium derived relaxing factor
EDTA	Ethylene-diamine-tetra acetic acid
eNOS	Endothelial nitric oxide synthase
ET-1	Endothelin-1
FDA	Food and Drug Administration
FMD	Flow mediated dilatation
GFR	Glomerular filtration rate
GTN	Glyceryl trinitrate
HbA1c	Haemoglobin A1c
HDL	High density lipoprotein
Hs-CRP	High sensitivity C- reactive protein
IDDM	Insulin dependent diabetes mellitus
IDF	International Diabetes Federation
Ig	Immunoglobulin
IMT	Intimal medial thickness
IMVS	Institute of Medical and Veterinary Science
LDL	Low density lipoprotein

LED	Light emitting diode
MTHF	Methyltetrahydrofolate
MTHFR	Methylene tetrahydrofolate reductase
NADPH	Nicotinamide Adenine Dinucleotide Phosphate (reduced)
NF- κ B	Nuclear factor kappa B
NO	Nitric oxide
ORPS	Oxford Regional Prospective Study
PAI-1	Plasminogen activator inhibitor-1
PGA	Pteroylmonoglutamate
PKC	Protein kinase C
PLP	Pyridoxal 5'-phosphate
RAGE	Receptors for AGE
RCT	Randomised Controlled Trial
ROS	Reactive oxygen species
SAH	S-adenosyl-L-homocysteine
T1DM	Type 1 Diabetes Mellitus
TGF- β	Transforming growth factor- β
tHcy	Total plasma homocyst(e)ine
TSH	Thyroid stimulating hormone
U.S.	United States
VEGF	Vascular endothelial growth factor
VD	Vessel diameter
VLDL	Very low density lipoprotein
vWF	von Willebrand Factor
WCH	Women's and Children's Hospital

Units

$\mu\text{g}/\text{min}$	micrograms per minute
$\mu\text{mol}/\text{l}$	micromoles per litre
μg	micrograms
$\mu\text{g}/\text{l}$	micrograms per litre
$^{\circ}\text{C}$	degrees Celsius
cm	centimetres
kg	kilogram
kg/m^2	kilograms per square metre
m/s	metres per second
mg/day	milligrams per day
mg/l	milligram per litre
mm	millimetre
mmHg	millimeters mercury
mmol/l	millimoles per litre
nmol/l	nanomoles per litre
units/kg	units per kilogram